The global plant-based vaccines market is expected to reach US$ 2,672.05 million by 2028 from US$ 1,143.72 million in 2021, growing at a CAGR of 12.9 % from 2021 to 2028. Increasing research & development (R & R&D) activities and the growing prevalence of infectious diseases are fueling the market’s growth. However, the potential risk of contamination and environmental risks of manufacturing the vaccines are expected to restrain the market growth during the forecast period. Plant-based vaccines can be made in a cost-effective way and produced on a large scale.Patients can readily accept these vaccines.
Moreover, these vaccines are stable for long-term antigen storage.They also help to reduce the economic burden of infectious disease globally.
Various plants, such as potato, rice, maize, tomato, carrot, tobacco, soybean, and peanut, have been used to develop plant-derived vaccines.The choice of the plant depends on the route of administration of the vaccine.
Various clinical trials are being conducted to develop plant-based vaccines in therapeutic indications such as influenza, flu, and Ebola virus. Infectious disorders or diseases are caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungus, and they can be transmitted from one person to another either directly or indirectly.These diseases can be divided into three categories – diseases that cause high levels of mortality, diseases that inflict a large load of disability on populations, and diseases that—due to their rapid and unexpected spread—can have serious global consequences.
Many of the significant health factors and infectious disease causes are beyond the health sector’s direct control. The rising prevalence of infectious diseases such as COVID-19, influenza, the common cold, tuberculosis (TB), hepatitis A and B is expected to flourish the demand for plant-based vaccines during the forecast period.On December 31, 2019, a COVID-19 case was first detected in Wuhan, China.
On March 11, 2020, the World Health Organization proclaimed COVID-19 a pandemic.COVID-19’s rapid proliferation is posing a challenge to the healthcare systems around the world.
Hospitals and intensive care units (ICUs) in many nations are overburdened or on the verge of collapsing.As a result, the most efficient use of healthcare resources is required.
With limited access to breathing equipment, skilled critical care employees, or protected patient monitoring systems, healthcare providers are compelled to treat extremely ill patients. The endeavor to keep COVID-19 patients from deteriorating and being admitted to the ICU is enormous. To slow the spread of the SARS-CoV-2 virus and prevent future outbreaks, the need for new diagnostics, treatments, and vaccinations is high. Malaria is the most common tropical human disease caused by protozoan parasites, with an increasing incidence and mortality rate.Furthermore, there are currently no licensed vaccinations for this disease, fueling the need to develop an effective and reliable anti-malaria vaccine that can protect humans from various parasitic infection stages containing various malaria antigens.
For example, according to the WHO figures from July 2018, there were 216 million malaria cases worldwide in 2016, with 445,000 deaths reported.The worldwide plant-based vaccine market is expected to rise due to rising influenza incidence rates.
According to the Centers for Disease Control and Prevention (CDC), in the US, influenza caused 49,000,000 symptomatic illnesses and 79,000 fatalities in 2017–2018. Hence, the rising number of infectious diseases worldwide is anticipated to boost the growth of the plant-based vaccines market during the forecast period. Based on application, the global plant-based vaccines market is segmented into influenza, zika virus, Ebola virus, poultry disease, COVID-19, and others.The influenza segment held the largest share of the market.
However, the COVID-19 segment is anticipated to register the highest CAGR of 13.8% in the market during the forecast period. A few of the major primary and secondary sources referred to while preparing the report on the plant-based vaccines market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and the National Center for Biotechnology Information (NCBI).
Our reports have been used by over 10K customers, including:
The frozen tissues samples market is projected to reach US$ 105,045.91 Thousand by 2028 from US$ 44,399.07 Thousand in 2021; it is estimated to grow at a CAGR of 13.1% during 2021-2028. The report highlights trends prevailing in the market and the factors driving it.The growth of the frozen tissues samples market is attributed to the...
17 pages •
By Euromonitor International
• Jan 2022
Continuing depopulation will resume in 2022-2040 due to natural decrease and negative rates of net migration. Ageing will accelerate, impacting consumer trends and increasing pressure on state resources. Life expectancy is set to increase but challenges remain, particularly in male health. Urbanisation will continue to be rapid. As the economy...
The anatomic pathology market is projected to reach US$ 33,145.78 million by 2028 from US$ 21,488. 41 million in 2021; it is estimated to grow at a CAGR of 6.4% from 2021 to 2028. Factors such as increase in the prevalence of cancer and other diseases, and growing focus on personalized medicines. However, the lack of skilled professionals...
The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on...
The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028. The market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Anatomic pathology track and trace solutions market projected to grow at a CAGR of 10.4% The anatomic pathology track and trace solutions market is projected to reach USD 695.7 million by 2023 from USD 424.2 million in 2018, at a CAGR of 10.4% from 2018 to 2023. The increasing volume of diagnostic tests performed in anatomic...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.